Presenter: Prof. Dr. Willeke van Roon-Mom
Date: November 18th, 2021
Time: 8am Pacific Daylight Time / 11am Eastern Daylight Time / 5pm (17.00) Central European Time
After the development of Milasen in the United States, there has been an increase in the development of antisense oligonucleotide therapies for patients with unique mutations. However the regulatory landscape is very different in the United States and Europe. In this presentation I will outline how The Dutch Center for RNA Therapeutics (DCRT) aims to facilitate the development of tailor-made splice modulating RNA therapies in The Netherlands and Europe. The DCRT is a nonprofit consortium of three medical centers that aligns the Dutch initiative with other initiatives in Europe and world-wide.